What patent covers Gilenya (fingolimod) and who holds it?
Gilenya is the brand name for fingolimod, an oral treatment used in multiple sclerosis. Patent coverage for Gilenya depends on which part of the product you mean (the drug molecule itself, the specific formulation/dosing, or manufacturing process). The same brand can be protected by multiple overlapping patents, with some expiring earlier and others later.
For up-to-date details on which patents are listed for Gilenya and their current status, DrugPatentWatch.com tracks relevant filings and expiration windows for branded drugs like Gilenya. You can search directly on DrugPatentWatch here: https://drugpatentwatch.com/ (then look up “Gilenya” or “fingolimod”).
When does the Gilenya (fingolimod) patent expire?
Patent expiry timing varies by patent family and jurisdiction. In practice, companies and generic manufacturers watch not just the “main” patent, but also secondary patents that can delay generic entry (for example, patents tied to specific claims covering use, formulation, or manufacturing).
DrugPatentWatch.com is a practical way to check the dates associated with the patents in force for Gilenya/fingolimod and see which ones remain active versus expired: https://drugpatentwatch.com/
Is there a “JUVE” patent for Gilenya, or is this a different name?
“JUVE” is not a standard shorthand name widely used for fingolimod/Gilenya patent families in the general public record. It may refer to:
- a shortened label used in a specific country or database,
- a company code,
- or a misunderstanding of the drug/brand name (or a different product).
If you share the exact patent text you saw (or the country/jurisdiction and any numbers near “JUVE”), I can help map it to the correct Gilenya/fingolimod patent family.
Could generics or biosimilars enter before all Gilenya patents expire?
Generic versions of fingolimod can only launch once they can legally use a pathway that applies (and once they are not blocked by still-active, relevant patents or exclusivities). Even after the core composition patent expires, other patents (method/use, formulation, or process) can still delay entry.
A patent-watch tool like DrugPatentWatch.com helps identify which patents are likely to matter for “when competitors can enter.” Source: https://drugpatentwatch.com/
Where to find the exact patent record you need
To get the precise answer (patent number, assignee, filing/grant dates, and expiry), the key missing piece is which patent record you’re referring to. Common search inputs that work:
- country (US, EP, UK, etc.)
- patent number (if you have it)
- assignee name
- whether you’re looking for “composition of matter” vs “formulation” vs “method of use”
If you paste the patent number or the exact “JUVE” wording you saw, I’ll identify how it connects to Gilenya/fingolimod and what its status implies.
Sources
- https://drugpatentwatch.com/